Trail receptor-targeted therapy: strategies to enhance DR4- and DR5-induced apoptosis
van Roosmalen, Ingrid

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version
Publisher's PDF, also known as Version of record

Publication date:
2014

Link to publication in University of Groningen/UMCG research database

Citation for published version (APA):
THE ER STRESS INDUCER DMC ENHANCES TRAIL-INDUCED APOPTOSIS IN GLIOBLASTOMA

Ingrid A.M. van Roosmalen*, Carlos R. Reis*, Rita Setroikromo, Saravanan Yuvaraj, Justin V. Joseph, Pieter G. Tepper, Frank A.E. Kruyt, Wim J. Quax

* these authors contributed equally to this work

SpringerPlus 2014; 3: 495
ABSTRACT

Background
Glioblastoma multiforme (GBM) is the most aggressive malignant brain tumour in humans and is highly resistant to current treatment modalities. We have explored the combined treatment of the endoplasmic reticulum (ER) stress-inducing agent 2,5-dimethyl-celecoxib (DMC) and TNF-related apoptosis-inducing ligand (TRAIL-WT) or the DR5-specific TRAIL D269H/E195R variant as a potential new strategy to eradicate GBM cells using TRAIL-resistant and -sensitive GBM cells.

Methods
GBM cell lines were investigated for their sensitivity to TRAIL, DMC and combination of both agents. Cell viability was measured by MTS assay and apoptosis was assessed by Annexin V/PI and acridine orange staining. Caspase activation and protein expression levels were analysed with Western blotting. Death Receptor (DR) cell surface expression levels were quantified by flow cytometry. DR5 expression was increased in U87 cells by ectopic expression using a retroviral plasmid and survivin expression was silenced using specific siRNAs.

Results
We demonstrate that A172 expresses mainly DR5 on the cell surface and that these cells show increased sensitivity for the DR5-specific rhTRAIL D269H/E195R variant. In contrast, U87 cells show low DR cell surface levels and is insensitive via both DR4 and DR5. We determined that DMC treatment displays a dose-dependent reduction in cell viability against a number of GBM cells, associated with ER stress induction, as shown by the up-regulation of glucose-regulated protein 78 (GRP78) and CCAAT/-enhancer-binding protein homologous protein (CHOP) in A172 and U87 cells. The dramatic decrease in cell viability is not accompanied by a correspondent increase in Annexin V/PI or caspase activation typically seen in apoptotic or necrotic cells within 24 h of treatment. Although DMC did not affect DR5 expression in the GBM cells, it increased TRAIL-induced caspase-8 activation in both TRAIL-sensitive and -resistant cells, indicating that DMC potentiates initiator caspase activation in these cells. In A172 cells, sub-toxic concentrations of DMC greatly potentiated TRAIL-induced apoptosis. Furthermore, DMC strongly reduced survivin expression in A172 and U87 cells and silencing of this anti-apoptotic protein partially sensitized cells to TRAIL-induced apoptosis.

Conclusion
Our findings corroborate that DMC is a promising agent against GBM, and uncovers a potential synergistic cooperation with TRAIL in this highly malignant cancer.
BACKGROUND

Glioblastoma multiforme (GBM) has been classified as a WHO grade IV glioma. This type of tumour is the most common and aggressive of the glial tumours. Despite the available treatment modalities, consisting of surgical resection followed by a combination of radiation and chemotherapy, the median survival rate ranges from 12-15 months [1]. To improve the prognosis of GBM patients, novel therapies are therefore required.

TNF-related apoptosis-inducing ligand (TRAIL), a member of the TNF superfamily, has previously been shown to be a promising anti-cancer therapeutic agent [2, 3] for its ability to induce apoptosis in a variety of tumour cells, without affecting normal cells [4, 5]. Trimeric recombinant human TRAIL (rhTRAIL) is able to induce apoptosis upon binding to either death receptor 4 (DR4, TRAIL-R1) or death receptor 5 (DR5, TRAIL-R2). TRAIL receptor-specific apoptosis-inducing variants have previously been generated, displaying enhanced affinity for either DR4 or DR5, resulting in more potent apoptosis induction in several tumour cells [6, 7]. Binding of TRAIL to its cognate death receptors triggers the establishment of the death-inducing signalling complex (DISC), composed of FAS-associated death domain (FADD) and pro-caspase-8. Upon DISC formation, the initiator pro-caspase-8 is processed into active caspase-8, which is able to either directly cleave effector caspases-3 and -7, or cleave Bid into truncated Bid (tBid). The latter results in the release of mitochondrial factors, including cytochrome c, subsequently leading to caspase-9 cleavage and further activation of effector caspases, resulting in irreversible apoptosis [8]. In general, GBM cells have been found to be highly resistant to TRAIL-induced apoptosis due to a variety of reasons, such as moderate to low expression of DR4 and DR5 [9, 10], the up-regulation of the anti-apoptotic proteins c-FLIP, Bcl-2 and survivin [9, 11-14], or the down-regulation of critical pro-apoptotic proteins such as caspase-8 and Bak [9, 12, 15, 16].

Recently, an increasing number of reports have shown the therapeutic relevance of inducers of endoplasmic reticulum (ER) stress in cancer, also as sensitizers for TRAIL-based therapies [17-23]. ER stress can be triggered by alterations in normal ER function, such as the accumulation of unfolded, misfolded or excessive proteins, imbalances of lipids or glycolipids, or changes in the redox or ionic conditions within the ER lumen [24-26]. The ER stress inducer 2,5-dimethyl-celecoxib (DMC) is an analogue of the cyclooxygenase-2 (COX-2)-selective non-steroidal anti-inflammatory drug (NSAID) celecoxib. At the molecular level, DMC lacks the COX-2 inhibitory function present in celecoxib, whereas the ER stress-activating potential is enhanced by DMC [27, 28]. DMC has also been shown to block cell proliferation in several tumour cell culture models [28, 29] and demonstrated anti-tumorigenic activity in vivo [29]. ER stress appears to be initiated within seconds after the addition of DMC to cultured cells, through the inhibition of the sarcoplasmic/ER calcium ATPase (SERCA) [27, 30, 31]. Consequently, an ER stress response (ESR) is triggered, which is characterized by the up-regulation
of ER molecular chaperones, including the pro-survival regulator glucose-regulated protein 78 (GRP78), therefore facilitating protein folding, translocation of polypeptides across the ER membrane, and the activation of transmembrane ER stress sensors [32]. Another ER stress indicator is the enhanced expression of the pro-apoptotic CCAAT/enhancer-binding protein homologous protein (CHOP) [33-36], which has been found to up-regulate DR5 expression in several cancer cell types [17-22, 37]. ER stress has also been reported to down-regulate anti-apoptotic proteins, including c-FLIP [17-20], Bcl-2 [18, 37, 38] and survivin [18, 23]. Moreover, prolonged activation of ER stress can lead to the activation of caspase-4 [27, 36, 39] and -7 [28, 36] resulting in apoptosis.

In this study we have explored the ability of DMC to enhance TRAIL-induced apoptosis in GBM cells. We demonstrate that A172, but not U87, is sensitive for apoptosis induced by rhTRAIL, and especially for the DR5-specific TRAIL variant D269H/E195R. DMC was able to significantly reduce cell viability of several GBM cell lines. We show that both sub-toxic and toxic doses of DMC significantly enhance TRAIL-induced apoptosis in A172 cells. Taken together, DMC in combination with rhTRAIL appears to be a promising therapeutic approach for the treatment of a subset of GBM cells.

**MATERIALS AND METHODS**

**Cell lines and chemicals**

Human glioblastoma cell lines A172, U87, SNB75 and U251 were obtained from the American Type Culture Collection (ATCC). Cells were cultured in DMEM with 4.5 g/L D-glucose (Gibco, Life Technologies) supplemented with 10% foetal calf serum, 100 units/mL penicillin and 100 μg/mL streptomycin in a humidified incubator at 37 °C containing 5% CO₂. 2,5-Dimethyl-celecoxib (DMC) was produced as described earlier [40, 41]. Celecoxib (CXB) was purchased from Key Organics. DMC and CXB were both dissolved in DMSO; the control with only solvent (DMSO) showed no toxicity. RhTRAIL wild-type (WT), DR4-specific TRAIL variant 4C7 and DR5-specific TRAIL variant D269H/E195R (amino acids 114-281) were constructed and produced as described earlier [6, 7].

**Cell viability and apoptosis assays**

Cell viability was measured using the MTS assay, a colorimetric method in which viable cells reduce 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) to a formazan product. Cells were seeded in triplicate in 96-well plates at a cell density of 10,000 cells/well. After 24 h, cells were treated for 24 h with concentrations ranging from 0 to 250 ng/mL of rhTRAIL WT or D269H/E195R and/or 0 to 100 μM DMC in a final volume of 0.15-0.2 mL; reagents and ligands were serially diluted in cell culture medium. Cells were incubated with the MTS reagent according to the manufacturer’s instructions (G3581, Promega). Cell viability was determined by measuring the absorption at 492 nm on a microplate reader (Thermo Labsystems).
Apoptosis induction was measured using Annexin V-FITC and propidium iodide (PI) staining and quantified by flow cytometry. Cells were seeded in 6-well plates 24 h prior to treatment. The next day, cells were treated for 24 h with 0, 25 or 50 µM DMC. After treatment, cells were harvested and washed with calcium buffer (10.9 µM HEPES, 140 µM NaCl, 2.5 µM CaCl$_2$). Cell pellets were resuspended in 60 µL calcium buffer complemented with 5 µL Annexin V-FITC (IQP-120F, IQ Products) and incubated for 20 minutes on ice. Cells were washed and resuspended in 0.5 µg/mL PI (P4170, Sigma Aldrich) diluted in calcium buffer and left on ice until analysis. Cells were analysed using a FACSCalibur flow cytometer (BD).

Visualisation of apoptosis was accomplished using acridine orange. Cells were seeded in triplicate in 96-well plates with 10,000 cells/well 24 h prior to treatment. Treatment consisted of rhTRAIL WT (0, 10 or 100 ng/mL), with or without DMC (0, 25 or 50 µM) as indicated. After 24 h incubation, cells were stained with 2 µL/well 10x diluted 1 mg/mL acridine orange solution and incubated for 10 minutes. Plates were spun down for 10 minutes at 900 rpm. Fluorescence microscopy was used to determine the presence of apoptotic bodies and/or chromatin condensation.

**Western blotting**

GBM cells were seeded in T25 culture flasks at a density of 750,000 cells/flask 24 h prior to treatment. For TRAIL-induced apoptosis, A172 cells were treated for 5 h and U87 for 24 h, since apoptosis is induced quickly in A172 cells. Cells were treated with rhTRAIL WT (0, 10 or 100 ng/mL), with or without DMC (0, 25 or 50 µM). After treatment, cells were harvested and lysed using the M-PER Mammalian Protein Extraction Reagent (PIERCE, Thermo Scientific) with additional Protease Inhibitor Cocktail, EDTA-Free (100x; Thermo Scientific). Protein concentrations were determined using a Bradford assay (Bio-Rad Laboratories). Equal amounts of protein for each sample were loaded per lane on pre-cast 4-12% SDS-PAGE gels (Invitrogen) and transferred onto Immobilon-FL PVDF 0.45 µm membranes (Millipore). Subsequently, the membranes were blocked for 1h at room temperature in blocking buffer (Rockland). Western Blot membranes were probed overnight at 4 °C. The following primary antibodies were used: caspase-3 (9662, 9661), caspase-8 (9746), caspase-9 (9501, 9508), c-FLIP (8510), CHOP (2895), PARP (9542) (Cell Signaling), COX-2 (160112, Cayman Chemical), GRP78 (sc-13968, Santa Cruz) and survivin (AF886, R&D Systems). Goat-α-mouse-IRDye (800CW; 926-32210 and 680; #926-32220) or goat-α-mouse-IRDye (800CW; 926-32211 and 680; #926-32221) secondary antibodies (Westburg) were used for detection using a LI-COR Odyssey Infrared Imaging System (Westburg). Membranes were probed with anti-β-actin (0869100, MP Biomedicals) to confirm equal loading.

**TRAIL receptor expression analysis**

GBM cells were harvested and washed with standard buffer (PBS/1% BSA). TRAIL receptor cell surface expression was determined using 10 µg/mL TRAIL-R1 (ALX-804-297), TRAIL-R2...
(ALX-804-298), TRAIL-R3 (ALX-804-344), TRAIL-R4 (ALX-804-299) (Alexis Biochemicals, Enzo Life Sciences.), DR5-01-1 (EXB-11-461, Exbio) or negative control mouse IgG1 (X0931, DAKO). Cells were incubated with primary antibodies for 1h. Subsequently, the cells were washed and incubated for 1h with R-phycoerythrin (PE) conjugated goat anti-mouse antibody (1010-09, Southern Biotech) or Alexa Fluor 488 conjugated goat anti-mouse antibody (A-11001, Invitrogen). Receptor cell surface expression was analysed using a FACSCalibur flow cytometer (BD).

**Retroviral-based DR5 overexpression**

DR5-TV1 was amplified from a plasmid (kindly provided by MSD) using forward (5'-agatctatggaacaacggggacagaacg-3') and reverse (5'-cgcgaattcttaggacatggcagagt-3') primers containing BglII and EcoRI restriction sites. The PCR product was cloned into pMSCV-tdTomato, a retrovirus expression system (kindly provided by prof. J.J. Schuringa). For the packaging of the retroviral particles, 2*10^6 HEK293 cells were plated in 94.0 mm cell culture dishes. The next day, cells were transfected with either pMSCV-tdTomato vector expressing DR5-TV1 or an empty vector, using CaCl₂. After 24 h, the medium containing virus particles was harvested, filtered and added to U87 cells, which were plated the day before at a density of 0.25*10^6 U87 cells in wells of a 6-wells plate. The U87 cells were exposed to the viral particles for 48h after which the virus was removed and fresh medium was added. Mixed populations of U87-empty or U87-DR5 cells were cultured in DMEM with 4.5 g/L D-glucose (Gibco, Life Technologies) supplemented with 10% foetal calf serum, 100 units/mL penicillin, and 100 µg/mL streptomycin in a humidified incubator at 37 °C containing 5% CO₂. U87 transduced cells, containing constructs encoding tdTomato, were sorted using a fluorescent activated cell sorter.

**RNA interference**

A172 cells were seeded in 6-wells plates at a density of 200,000 cells/well. The next day, the subconfluent cultures were incubated with unsupplemented OptiMEM medium (Gibco, Life Technologies) and transfected with 133 nM survivin (sc-29499, Santa Cruz) or negative control small interfering RNA (siRNA) (SR-CL000-005, Eurogentec) using Oligofectamine Transfection Reagent (12252-011, Invitrogen) according to the manufacturer’s protocol. 24 h after siRNA transfection, cells were seeded and treated as indicated for MTS assays (24 h treatment) or Western blot analysis (5 h treatment).

**RESULTS**

**A172 but not U87 cells are sensitive to TRAIL-induced apoptosis primarily via DR5**

Analysis of receptor expression by flow cytometry revealed distinct differences in TRAIL receptor membrane expression levels of A172 and U87 cells (figure 1A). While A172 cells express high levels of DR5, U87 cells showed significantly lower levels of surface DR5. DR4 expression was found to be low in A172 and it was undetectable in U87. Low
decoy receptor expression was also detected in A172 cells and absent in U87 cells. Since both A172 and U87 cells show distinct expression profiles of DR5 on the membrane and low or absent expression of DR4, these cells were exposed to different concentrations of rhTRAIL WT, and the previously described DR4-selective variant (rhTRAIL 4C7) [6, 7] and DR5-selective variant (rhTRAIL D269H/E195R) [6]. A172 cells showed a clear dose dependent sensitivity to rhTRAIL, when treated with either rhTRAIL WT or rhTRAIL D269H/E195R, but was completely resistant to rhTRAIL 4C7. The mutant D269H/E195R was more effective in reducing cell viability in A172 when compared to rhTRAIL WT. In contrast,

Figure 1. A172 cells are sensitive to TRAIL-induced apoptosis in a dose-dependent manner. (A) Cell surface expression of the various TRAIL receptors was determined on A172 and U87 cells using flow cytometry analysis and expressed as the Mean Fluorescence Intensity (MFI) ratio. (B) Western blot analysis of A172 and U87 cells treated with 0, 10 or 100 ng/mL rhTRAIL WT for 5 h or 24 h, respectively. β-actin serves as a loading control. (C) Viability of A172 and U87 cells was assessed after treatment with various concentrations (0-1000 ng/mL) of rhTRAIL WT, 4C7 or D269H/E195R for 24 h as measured by MTS assays. Error bars represent S.E.M. of three independent experiments.
U87 cells were highly resistant to all rhTRAIL ligands (figure 1B). Afterwards, Western blot analysis was used to detect cleavage of caspases and PARP after treatment with 10 (low) or 100 (moderately high) ng/mL rhTRAIL WT. Since A172 cells proved to be TRAIL sensitive these cells were exposed to rhTRAIL WT for 5 h in order not to lose the cells due to massive cell death. The TRAIL resistant U87 cells were treated for 24 h. Accordingly, rhTRAIL WT exposure resulted in clear cleavage of caspase-8, -9, -3 and PARP in A172 cells, whereas in U87 cells, even upon treatment with 100 ng/mL rhTRAIL WT, no activation of these apoptotic-related proteins was observed (figure 1C). We then tested if the differential TRAIL-sensitivities observed in A172 and U87 could be explained by the differences at the level of surface DR5 expression, with low levels of death receptor expression in U87 cells causing the insensitivity to both rhTRAIL WT and rhTRAIL D269H/E195R.

**Ectopic overexpression of DR5 in U87 cells does not enhance TRAIL sensitivity**

To investigate whether enhancement of DR5 expression could trigger TRAIL-induced apoptosis, U87 cells were transduced with either an empty retroviral vector (U87-control) or a vector expressing DR5 (U87-DR5). This vector contains the gene for tdTomato, allowing for the isolation of transduced tdTomato-positive cells by FACS sorting. DR5 expression levels were determined by flow cytometry using TRAIL receptor-specific antibodies labelled with the Alexa Fluor 488 dye, since PE-labelled antibodies would result in overlapping emission spectra with tdTomato (figure 2A). Notably, a large shift in mean fluorescence intensity (MFI) levels was measured when Alexa Fluor 488 was used compared to previous results with the PE dye. Although the elevated surface levels of DR5 in U87-DR5 cells is similar to the DR5 expression level observed in A172 cells, U87-DR5 cells did not show enhanced sensitivity to rhTRAIL WT or rhTRAIL D269H/E195R even at high concentrations of rhTRAIL (up to 1000 ng/mL) (figure 2B). These results indicate that DR5 overexpression per se is not sufficient to sensitize U87 cells to TRAIL-induced apoptosis.

**DMC decreases cell viability of GBM cells and enhances TRAIL-induced apoptosis in A172 cells**

Next, we examined the potential of the ER stress inducer DMC alone and in combination with TRAIL across several GBM cell lines. We started by determining the effect of DMC on the cell viability of GBM cells. As shown in figure 3A, DMC was able to efficiently promote reduction in cell viability as measured by MTS in all the GBM cell lines studied. SNB75 cells showed the highest sensitivity to DMC, whereas U251, A172 and U87 cells were almost equally sensitive to DMC (figure 3A).

To evaluate if the DMC effects observed in these cells were correlated with the induction of apoptosis or necrosis, A172 and U87 cells were treated with either a sub-toxic (25 µM) or a moderate cytotoxic (50 µM) dose of DMC for 24 h and stained with Annexin V/PI, with Annexin V positive cells representing the apoptotic fraction. Figure 3B shows that the addition of a high concentration of DMC alone resulted in a minor increase in
Annexin V positivity. In addition, after DMC treatment the level of Annexin V/PI+ cells were comparable to untreated cells. Together with the results obtained using MTS assays, these results suggest that treating cells with concentrations up to 50 µM DMC did not result in apoptosis or necrosis in these cells, contrasting with the significant reduction seen when using the MTS assay. In order to assess if DMC induced ER stress, expression levels of GRP78 and CHOP, two established markers of ER stress, were examined. Consistent with the previously described role of DMC in ER-stress induction, Western blot analysis showed a clear up-regulation of GRP78 and CHOP upon treatment with 50 µM of DMC (figure 3C).

Next, the effect of combined exposure to rhTRAIL WT and 0, 25 or 50 µM of DMC was examined in these differentially TRAIL-responsive GBM cell lines. In this assay, A172 cells treated for 24 h with 125 ng/mL rhTRAIL without DMC showed already ~75% reduction in cell viability (IC_{50}: ~36 ng/mL), which was strongly enhanced after combination with DMC (25 µM: ~10%, IC_{50}: ~12 ng/mL and 50 µM: ~2%, IC_{50}: ~1 ng/mL) (figure 4A). Notably, the cell viability of A172 cells was reduced with approximately 86% using only 31.3 ng/mL of rhTRAIL
WT in combination with 25 µM of DMC, when compared to TRAIL WT in combination with 0 µM DMC, where approximately 47% reduction in cell viability could be attained. Therefore, TRAIL sensitivity can be enhanced in A172 cells by co-treatment with DMC. U87 cells remained TRAIL-resistant (0 µM: ~99%), and although the single treatment with DMC was able to lower the cell viability of U87 cells (25 µM: ~87%; 50 µM: 66%), no additive or synergistic effects could be found in combination with rhTRAIL WT (figure 4A). Since DMC is an analogue of celecoxib, we further tested the sensitivity of these cell lines to

**Figure 3. DMC reduces cell viability and induces ER stress in GBM cell lines.** (A) Cell viability was assessed in a panel of GBM cell lines after 24 h exposure to 0-100 µM of DMC using a MTS assay. Error bars represent S.E.M. of three independent experiments. (B) A172 and U87 cells were treated with 0, 25 or 50 µM DMC for 24 h after which apoptosis induction was determined using Annexin V/PI using flow cytometry. (C) Treatment of A172 and U87 cells with 0, 25 or 50 µM DMC for 24 h resulted in a dose-dependent up-regulation of CHOP and GRP78 proteins levels as showed by Western blotting. β-actin serves as a loading control. Presented data are representative for at least three independent experiments and mean cell viability levels ± S.E.M. are shown.
celecoxib treatment. A172 and U87 showed similar IC₅₀ values of approximately 88 µM for both A172 and U87 (supplementary figure 1). Next, DMC or celecoxib were tested side-by-side in combination with rhTRAIL WT. Interestingly, the combination of TRAIL/DMC (IC₅₀: ~57 µM) was shown to be more effective than TRAIL/celecoxib (IC₅₀: ~88 µM) (supplementary figure 2). Since DMC is a more potent ER stress inducer than celecoxib and does not target COX-2 [27, 28], these results suggest that ER stress activation is closely related to the reduction of cell viability, and subsequently, the enhancement of TRAIL-induced cytotoxicity in these cells.

To confirm that the combinatorial effects described above were correlated with enhanced apoptosis activity, the effect of DMC on TRAIL-induced caspase cleavage was
further analysed. Figure 4B shows that after 5 h treatment, A172 cells display a significant activation of the caspases-8, -9, -3 and PARP cleavage when exposed to rhTRAIL WT alone, and enhanced cleavage when combined with DMC. Treatment with 100 ng/mL of rhTRAIL WT and 50 µM DMC resulted in massive cell death in A172 cells. Notably, DMC alone did not induce any activation of downstream apoptosis-related proteins, as indicated by a lack of caspase activation or PARP cleavage, and in agreement with our earlier observations using Annexin V staining assays (figure 3B). Furthermore, acridine orange staining of DMC-treated cells showed no evidence of nuclear condensation and nuclear/cellular fragmentation, as shown after rhTRAIL WT treatment in A172 cells, but it does appear that DMC reduces cell proliferation, especially in A172 cells (figure 5). Notably, in U87 cells the combined treatment of rhTRAIL WT with 50 µM DMC led to activation of the initiator pro-caspase-8 but no subsequent pro-caspase-9, -3 or PARP cleavage. Treatment of U87 cells with both TRAIL WT and DMC resulted in the down-regulation of pro-caspase-3 in this cell line (figure 4B). Finally, the effect of combined exposure to rhTRAIL WT and DMC was also examined in U87-control and U87-DR5 cells, with no significant effect of DMC on TRAIL-sensitivity being observed for these cell lines (supplementary figure 3).

**DMC down-regulates the anti-apoptotic protein survivin in A172 and U87 cells**

Previous studies have reported that ER stress can stimulate apoptosis induction not only by up-regulating pro-apoptotic proteins, such as DR5, but also by down-regulating anti-apoptotic proteins, such as c-FLIP [17-20], Bcl-2 [18, 37, 38] and survivin [18, 23]. Treatment with sub-toxic or toxic concentrations of DMC did not affect the level of TRAIL receptors on the surface of both A172 and U87 cells (figure 6A). Interestingly, Western Blot analysis showed that DMC treatment resulted in a significant down-regulation of survivin levels in both cell lines (figure 6B). Furthermore, c-FLIP expression levels were slightly down-regulated in U87 when treating these cells with DMC. Finally, DMC treatment did not increase the expression of DR5 or reduce the expression of the anti-apoptotic protein Bcl-2.

**Enhancement of TRAIL sensitivity in A172 cells by survivin siRNA**

In order to determine if down-regulation of survivin by DMC could explain the increase in TRAIL sensitivity observed in A172 cells, its expression was selectively silenced using a siRNA approach. Figure 7A shows efficient down-regulation of survivin upon siRNA transfection, which resulted in apoptosis activation as indicated by PARP cleavage. Interestingly, the addition of only 10 ng/mL rhTRAIL WT enhanced PARP cleavage in survivin knockdown cells (figure 7A), whereas the addition of D269H/E195R resulted in massive cell death, such that an insufficient amount of lysate could be prepared. Finally, analysis of cell viability upon TRAIL treatment in non-transfected, control-siRNA and survivin-siRNA treated cells indicate that the down-regulation of survivin slightly increased rhTRAIL WT- and rhTRAIL D269H/E195R-mediated apoptosis in A172 at low concentrations, when compared to both untransfected and control-siRNA treated cells (figure 7B).
Figure 5. DMC reduces proliferation in GBM cells. Acridine orange staining was used to visualize apoptosis in A172 (A) and U87 (B). Cells were treated with 0, 10 or 100 ng/mL rhTRAIL WT and 0, 25 or 50 µM DMC. After 24 h, cells were stained using acridine orange dye.
**DISCUSSION**

TRAIL is a promising anticancer therapeutic agent that is able to induce apoptosis in various tumour cells while leaving normal cells unharmed [4, 5]. Currently, many GBM cells show resistance to TRAIL-induced apoptosis due to various reasons, including low expression of DR4 and DR5 [9, 10], the up-regulation of anti-apoptotic proteins such as c-FLIP, Bcl-2 and survivin [9, 11-14], or the down-regulation of critical pro-apoptotic proteins such as caspase-8 and Bak [9, 12, 15, 16]. Recently, the use of ER stress inducers, like DMC, have raised great interest as potential anti-cancer agents and sensitzers for TRAIL-based therapies, since ER stress was reported to down-regulate important anti-apoptotic proteins, including c-FLIP [17-20], Bcl-2 [18, 37, 38] and survivin [18, 23]. Here, we investigated the cell death induction properties of DMC in a panel of GBM cells, as well as the potential of DMC in enhancing TRAIL-induced apoptosis in TRAIL-resistant and -sensitive GBM cells.
We find that A172 and U87 express predominantly DR5 but not DR4 on their surface, with different levels of expression observed between cell lines (figure 1A). The DR5-high expressing A172 cells were especially sensitive to apoptosis induced by the rhTRAIL variant D269H/E195R, while U87 cells were resistant to apoptosis induction via both DR4 and DR5 (figure 1B). Interestingly, the ectopic overexpression of DR5 in U87 cells does not lead to enhancement of TRAIL sensitivity, indicating that lowered surface death receptor levels is not the main reason for TRAIL resistance in this cell line, and further suggesting that downstream processes prevent the activation of the TRAIL-apoptosis cascade (figure 2A,B).

We further studied the impact of ER stress inducer DMC, alone and in the context of TRAIL-mediated apoptosis. We demonstrate that DMC is able to efficiently reduce the cell viability of a panel of GBM cells and induce ER stress as seen by the up-regulation of the ER stress proteins GRP78 and CHOP in A172 and U87 cells (figure 3). Although A172 and U87 show a clear dose-dependent reduction in cell viability upon treatment with DMC, this is not accompanied by an enhancement of Annexin V or PI staining in these two cell lines (figure 3B), the activation of caspases (figure 4B) or the appearance of nuclear condensation (figure 5), indicating that DMC did not trigger apoptosis or necrosis in these GBM cells after 24 hours incubation using the mentioned concentrations. However, looking at figure 5, it appears that DMC is reducing proliferation rates, especially in A172 cells.
The combination of rhTRAIL WT or the DR5-specific variant with middle or high concentrations of DMC resulted in a significant increase in apoptosis induction in A172, leading to nearly complete apoptosis induction at very low concentrations of the ligand rhTRAIL when combined with DMC (figure 4 and 5). Although the up-regulation of DR5 [17-22, 37] or down-regulation of c-FLIP [17-20], Bcl-2 [18, 37, 38] or survivin [18, 23, 29] have been previously described as molecular mechanisms accountable for the sensitizing effect of ER stress induction (or DMC treatment on TRAIL-induced apoptosis), we only detected down-regulation of survivin in these cell lines upon treatment with DMC (figure 6). Survivin down-regulation induced apoptosis in A172 cells and only slightly affected rhTRAIL WT and D269H/E195R sensitivity in this cell line (figure 7). The fact that survivin-mediated knockdown only partially affects the sensitivity of this cell line towards TRAIL-induced apoptosis indicate that other mechanisms, perhaps ER-stress independent, may further contribute to the synergistic effects observed for TRAIL in combination with DMC. Furthermore, the depletion of survivin by siRNA led to the induction of apoptosis in A172, contrasting to the lack of clear apoptosis-inducing activity by the ER stress agent DMC.

Recently, Kardosh et al. have assigned the anti-tumour effect of DMC to the inhibition of cell proliferation through the down-regulation of cyclins A and B and the consequent loss of cyclin-dependent kinase activity. In that report, the authors have demonstrated the dose-dependent down-regulation of cell cycle-regulatory proteins in the presence of 0, 25 and 50 µM of DMC or celecoxib [40]. A recent study by Ehrhardt et al. described the increased sensitivity to TRAIL-induced apoptosis in cell cycle-arrested tumour cells [42]. These findings, combined with our observation that synergistic effects can be observed when using DMC in combination with TRAIL in a subset of GBM cells, give us further insight in the pleiotropic nature of this class of compounds and their potential effects in further enhancing or sensitizing cancer cells to TRAIL-induced apoptosis.

In contrast to the results obtained for A172 cells, DMC was not sufficient to circumvent TRAIL-resistance in U87 and DR5 overexpressing U87 cells, even when both c-FLIP and survivin down-regulation was observed after treatment with 50 µM DMC. While the combined treatment of rhTRAIL WT with 50 µM DMC led to a clear activation of pro-caspase-8, subsequent cleavage of pro-caspase-9, -3 and PARP could not be detected. Intriguingly, combination treatment of U87 led to a significant reduction in the expression of pro-caspase-3. Yet, U87 cells remain resistant to TRAIL, likely due to reduced pro-caspase-3 expression levels or other persistent downstream mechanisms of resistance that are in place in this particular cell line. Although several mechanisms of caspase-3 down-regulation have been previously described [43-46], it is currently unclear how the combination of TRAIL/DMC results in reduction in pro-caspase-3 expression in this cell line.
CONCLUSIONS

Our data clearly shows DMC might be a potential anti-cancer agent for the treatment of GBM, that can further potentiate TRAIL-induced apoptosis in a subset of GBM. DMC alone appears to effectively decrease the cell viability of a panel of GBM cells. Importantly, reduction of cell viability by 24 h treatment with DMC did not lead to apoptosis or necrosis, but seems to be due to reduced proliferation. We find that the DMC-mediated down-regulation of survivin partially accounts for the mechanism of TRAIL sensitization in A172 cells. As rhTRAIL warrants high tumour selectivity and sub-toxic concentrations of DMC further sensitize these cancer cells to TRAIL, it will be important to assess how other cells, especially primary cells, respond to such combination modalities. Additionally, the anti-tumorigenic properties of DMC alone and in the context of co-treatment will require further in vitro and in vivo studies, especially considering how effective cancer-specific apoptosis induction may provide therapeutic opportunities for the treatment of GBM as well as many other cancers.

ACKNOWLEDGEMENTS

We would like to thank dr. Robbert Cool for providing us the rhTRAIL variants. This research was partly funded by The Dutch Technology Foundation (STW; grant 11056), European Fund for Regional Development (KOP/EFRO; grants 068 and 073) and the Ubbo Emmius Foundation of the University of Groningen.
REFERENCES


DMC- and TRAIL-INDUCED CELL DEATH IN GBM CELLS


**SUPPLEMENTARY INFORMATION**

Supplementary figure 1. A172 and U87 cells are less sensitive to celecoxib when compared to DMC. Cell viability was assessed after 24 h exposure of A172 (A) or U87 (B) to 0-100 µM of CXB or DMC using a MTS assay. Error bars represent S.E.M. of three independent experiments.
Supplementary figure 2. DMC is more potent in reducing cell viability when combined with TRAIL than celecoxib. Cell viability was assessed after 24 h co-treatment of A172 (A) or U87 (B) with rhTRAIL WT (0-250 ng/mL) and 0, 25 or 50 µM celecoxib (CXB) or DMC using MTS assays. Error bars represent S.E.M. of three independent experiments.
Supplementary figure 3. DR5 overexpression in U87 cells did not enhance sensitivity to TRAIL in combination with DMC. Viability was assessed after 24 h co-treatment of U87-control (A) or U87-DR5 (B) with 0-1000 ng/mL rhTRAIL WT and 0, 25 or 50 µM DMC using MTS assays. Presented data are representative for three independent experiments and mean cell viability levels ± S.E.M. are shown.